Drugs / 601
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04667897 | Jan 2021 → Jul 2022 | occlusion of tributary of retinal vein | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04667897 ↗ |
| Action | Inhibit | “anti-VEGF” NCT04667897 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-VEGF monoclonal antibody” NCT04667897 ↗ |
| Route | Intravitreal | “intravitreal use” NCT04667897 ↗ |